Eagle Pharmaceuticals, Inc. - stock earnings
EGRX Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 7, 2024 AfterMarket | - / 0.9996000000 | - | - / 58.9 million | - |
EGRX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q2 | 5.2 million USD | 64.6 million USD |
| 2023Q1 | 5.8 million USD | 66.3 million USD |
| 2022Q4 | 8.2 million USD | 60.7 million USD |
| 2022Q3 | -3.5 million USD | 65.9 million USD |
| 2022Q2 | -9.5 million USD | 74.1 million USD |
| 2022Q1 | 44.1 million USD | 115.9 million USD |
| 2021Q4 | -6.2 million USD | 42.3 million USD |
| 2021Q3 | -5.6 million USD | 39.9 million USD |
| 2021Q2 | 3.6 million USD | 48.1 million USD |
| 2021Q1 | -421000 USD | 41.2 million USD |
| 2020Q4 | 8.1 million USD | 49.9 million USD |
| 2020Q3 | 7.1 million USD | 49.9 million USD |
| 2020Q2 | -256000 USD | 41.9 million USD |
| 2020Q1 | -2.9 million USD | 46.0 million USD |
| 2019Q4 | 1.0 million USD | 48.3 million USD |
| 2019Q3 | -2.4 million USD | 41.1 million USD |
| 2019Q2 | 6.7 million USD | 56.7 million USD |
| 2019Q1 | 9.0 million USD | 49.8 million USD |
| 2018Q4 | 12.6 million USD | 56.1 million USD |
| 2018Q3 | 14.0 million USD | 51.3 million USD |
| 2018Q2 | 2.7 million USD | 59.3 million USD |
| 2018Q1 | 2.6 million USD | 46.6 million USD |
| 2017Q4 | 9.1 million USD | 46.8 million USD |
| 2017Q3 | 15.4 million USD | 63.0 million USD |
| 2017Q2 | 4.5 million USD | 50.1 million USD |
| 2017Q1 | 22.9 million USD | 76.8 million USD |
| 2016Q4 | 57.3 million USD | 81.1 million USD |
| 2016Q3 | 12.0 million USD | 37.8 million USD |
| 2016Q2 | 13.1 million USD | 40.9 million USD |
| 2016Q1 | -896000 USD | 29.6 million USD |
| 2015Q4 | 1.2 million USD | 18.2 million USD |
| 2015Q3 | -10.2 million USD | 5.7 million USD |
| 2015Q2 | -8.2 million USD | 6.0 million USD |
| 2015Q1 | 19.7 million USD | 36.3 million USD |
| 2014Q4 | -5.5 million USD | 5.6 million USD |
| 2014Q3 | -9.1 million USD | 2.8 million USD |
| 2014Q2 | -2.9 million USD | 5.8 million USD |
| 2014Q1 | -2.7 million USD | 5.0 million USD |
| 2013Q4 | -3.3 million USD | 5.5 million USD |
| 2013Q3 | 483329 USD | 4.6 million USD |
| 2013Q2 | 754576 USD | 5.1 million USD |
| 2013Q1 | -4.8 million USD | 2.5 million USD |
| 2012Q4 | -2.5 million USD | 1.5 million USD |
| 2012Q3 | -5.2 million USD | 1.3 million USD |
EGRX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2022 | 35.6 million USD | 316.6 million USD |
| 2021 | -8.6 million USD | 171.5 million USD |
| 2020 | 12.0 million USD | 187.8 million USD |
| 2019 | 14.3 million USD | 195.9 million USD |
| 2018 | 31.9 million USD | 213.3 million USD |
| 2017 | 51.9 million USD | 236.7 million USD |
| 2016 | 81.5 million USD | 189.5 million USD |
| 2015 | 2.6 million USD | 66.2 million USD |
| 2014 | -18.0 million USD | 19.1 million USD |
| 2013 | -6.0 million USD | 13.7 million USD |
| 2012 | -19.4 million USD | 2.5 million USD |
EGRX
Price: $4.87
52 week price:
Payout Ratio Range:
Earnings Per Share: 0.85 USD
P/E Ratio: 6.88
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 130600
Ebitda: 25.9 millionMarket Capitalization: 63.4 million